Dairy powerhouse unveils €300m functional nutrition pivot

Kerry Dairy Ireland has officially changed its corporate identity to Kinisla. Consequently, the business is launching a major expansion phase.

This comprehensive Kinisla strategy aims to drive commercially disciplined growth across global markets over the next five years. The majority farmer-owned enterprise will inject €300 million into advanced manufacturing, innovation, and carbon reduction.

Capital allocation for high-value performance

Financially, the business enters this new chapter with record operational momentum. Turnover advanced to €1.4 billion in 2025, while EBITDA rose to €86.8 million. To build upon this foundation, the board approved a targeted €300 million investment pipeline.

Furthermore, the company will create 100 new roles within central functions over the next 12 to 24 months. Management will allocate this funding into segments with the highest long-term margin potential. Specifically, nutritional ingredients and dairy consumer foods will receive the bulk of this capital.

Pat Murphy, chief executive of Kinisla, outlined the strategic intent behind the financial performance: “2025 was a landmark year for Kinisla and one that underlines the strength of the farmer-owned business we are building. We delivered a strong performance, with turnover of €1.4 billion and significant momentum across key parts of the portfolio, particularly nutritional ingredients and dairy consumer foods.”

Capitalising on the weight management shift

For product developers, Kinisla’s move addresses critical modern formulation hurdles. Rapid global adoption of GLP-1 weight management medications is structurally changing consumer food preferences. Patients on these therapies require smaller, highly concentrated, nutrient-dense options.

Kinisla is intentionally tailoring its ingredient pipeline to satisfy this surging consumer demand. The business provides clean-label protein fractions that integrate smoothly into wellness bars and ready-to-drink beverages.

Scaling advanced proteins and clinical solutions

Additionally, the investment directly backs Kinisla’s proprietary Ultranor milk protein range. This ingredient provides exceptional heat stability during demanding ultra-high temperature processing. Beverage manufacturers can formulate high-protein options without creating a chalky texture or unappealing mouthfeel.

Similarly, the company’s Hyprol hydrolysed proteins cater to specialised clinical nutrition brands. The R&D team can customise these hydrolysates to meet strict mineral limits for vulnerable patient groups. Meanwhile, Dairyborn functional cheeses provide optimised melt performance for international foodservice pizza lines.

James Tangney, chairman of Kinisla, emphasised that this focused commercial blueprint ensures long-term viability: “The investment we are committing to over the next five years is about building a business that delivers on milk price, sustainability, and long-term growth. Kinisla is the identity under which we will successfully build that future for our farmers and the communities connected to them.”